Table of Content

1 Inactivated Influenza Virus Vaccine Market Overview
1.1 Product Overview and Scope of Inactivated Influenza Virus Vaccine
1.2 Inactivated Influenza Virus Vaccine Segment by Type
1.2.1 Global Inactivated Influenza Virus Vaccine Market Value Comparison by Type (2024-2034)
1.2.2 Whole Virus Vaccine
1.2.3 Subunit Vaccine
1.3 Inactivated Influenza Virus Vaccine Segment by Application
1.3.1 Global Inactivated Influenza Virus Vaccine Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Inactivated Influenza Virus Vaccine Market Size Estimates and Forecasts
1.4.1 Global Inactivated Influenza Virus Vaccine Revenue 2024-2034
1.4.2 Global Inactivated Influenza Virus Vaccine Sales 2024-2034
1.4.3 Global Inactivated Influenza Virus Vaccine Market Average Price (2024-2034)
1.5 Assumptions and Limitations
2 Inactivated Influenza Virus Vaccine Market Competition by Manufacturers
2.1 Global Inactivated Influenza Virus Vaccine Sales Market Share by Manufacturers (2024-2024)
2.2 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Manufacturers (2024-2024)
2.3 Global Inactivated Influenza Virus Vaccine Average Price by Manufacturers (2024-2024)
2.4 Global Inactivated Influenza Virus Vaccine Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Inactivated Influenza Virus Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Inactivated Influenza Virus Vaccine, Product Type & Application
2.7 Inactivated Influenza Virus Vaccine Market Competitive Situation and Trends
2.7.1 Inactivated Influenza Virus Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Inactivated Influenza Virus Vaccine Players Market Share by Revenue
2.7.3 Global Inactivated Influenza Virus Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Inactivated Influenza Virus Vaccine Retrospective Market Scenario by Region
3.1 Global Inactivated Influenza Virus Vaccine Market Size by Region: 2024 Versus 2022 Versus 2034
3.2 Global Inactivated Influenza Virus Vaccine Global Inactivated Influenza Virus Vaccine Sales by Region: 2024-2034
3.2.1 Global Inactivated Influenza Virus Vaccine Sales by Region: 2024-2024
3.2.2 Global Inactivated Influenza Virus Vaccine Sales by Region: 2024-2034
3.3 Global Inactivated Influenza Virus Vaccine Global Inactivated Influenza Virus Vaccine Revenue by Region: 2024-2034
3.3.1 Global Inactivated Influenza Virus Vaccine Revenue by Region: 2024-2024
3.3.2 Global Inactivated Influenza Virus Vaccine Revenue by Region: 2024-2034
3.4 North America Inactivated Influenza Virus Vaccine Market Facts & Figures by Country
3.4.1 North America Inactivated Influenza Virus Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.4.2 North America Inactivated Influenza Virus Vaccine Sales by Country (2024-2034)
3.4.3 North America Inactivated Influenza Virus Vaccine Revenue by Country (2024-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Inactivated Influenza Virus Vaccine Market Facts & Figures by Country
3.5.1 Europe Inactivated Influenza Virus Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.5.2 Europe Inactivated Influenza Virus Vaccine Sales by Country (2024-2034)
3.5.3 Europe Inactivated Influenza Virus Vaccine Revenue by Country (2024-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Inactivated Influenza Virus Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Inactivated Influenza Virus Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.6.2 Asia Pacific Inactivated Influenza Virus Vaccine Sales by Country (2024-2034)
3.6.3 Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Country (2024-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Inactivated Influenza Virus Vaccine Market Facts & Figures by Country
3.7.1 Latin America Inactivated Influenza Virus Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.7.2 Latin America Inactivated Influenza Virus Vaccine Sales by Country (2024-2034)
3.7.3 Latin America Inactivated Influenza Virus Vaccine Revenue by Country (2024-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Inactivated Influenza Virus Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Inactivated Influenza Virus Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.8.2 Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Country (2024-2034)
3.8.3 Middle East and Africa Inactivated Influenza Virus Vaccine Revenue by Country (2024-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Inactivated Influenza Virus Vaccine Sales by Type (2024-2034)
4.1.1 Global Inactivated Influenza Virus Vaccine Sales by Type (2024-2024)
4.1.2 Global Inactivated Influenza Virus Vaccine Sales by Type (2024-2034)
4.1.3 Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2024-2034)
4.2 Global Inactivated Influenza Virus Vaccine Revenue by Type (2024-2034)
4.2.1 Global Inactivated Influenza Virus Vaccine Revenue by Type (2024-2024)
4.2.2 Global Inactivated Influenza Virus Vaccine Revenue by Type (2024-2034)
4.2.3 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2024-2034)
4.3 Global Inactivated Influenza Virus Vaccine Price by Type (2024-2034)
5 Segment by Application
5.1 Global Inactivated Influenza Virus Vaccine Sales by Application (2024-2034)
5.1.1 Global Inactivated Influenza Virus Vaccine Sales by Application (2024-2024)
5.1.2 Global Inactivated Influenza Virus Vaccine Sales by Application (2024-2034)
5.1.3 Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2024-2034)
5.2 Global Inactivated Influenza Virus Vaccine Revenue by Application (2024-2034)
5.2.1 Global Inactivated Influenza Virus Vaccine Revenue by Application (2024-2024)
5.2.2 Global Inactivated Influenza Virus Vaccine Revenue by Application (2024-2034)
5.2.3 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2024-2034)
5.3 Global Inactivated Influenza Virus Vaccine Price by Application (2024-2034)
6 Key Companies Profiled
6.1 CSL
6.1.1 CSL Corporation Information
6.1.2 CSL Description and Business Overview
6.1.3 CSL Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.1.4 CSL Inactivated Influenza Virus Vaccine Product Portfolio
6.1.5 CSL Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.2.4 GSK Inactivated Influenza Virus Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi Pasteur
6.3.1 Sanofi Pasteur Corporation Information
6.3.2 Sanofi Pasteur Description and Business Overview
6.3.3 Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.3.4 Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Portfolio
6.3.5 Sanofi Pasteur Recent Developments/Updates
6.4 Mylan
6.4.1 Mylan Corporation Information
6.4.2 Mylan Description and Business Overview
6.4.3 Mylan Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Mylan Inactivated Influenza Virus Vaccine Product Portfolio
6.4.5 Mylan Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Corporation Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.5.4 AstraZeneca Inactivated Influenza Virus Vaccine Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.6.4 Pfizer Inactivated Influenza Virus Vaccine Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Johnson & Johnson Inactivated Influenza Virus Vaccine Product Portfolio
6.7.5 Johnson & Johnson Recent Developments/Updates
6.8 Jiangsu Jindik Biotechnology Co., Ltd
6.8.1 Jiangsu Jindik Biotechnology Co., Ltd Corporation Information
6.8.2 Jiangsu Jindik Biotechnology Co., Ltd Description and Business Overview
6.8.3 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.8.4 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.8.5 Jiangsu Jindik Biotechnology Co., Ltd Recent Developments/Updates
6.9 Beijing Kexing Biological Products Co., Ltd
6.9.1 Beijing Kexing Biological Products Co., Ltd Corporation Information
6.9.2 Beijing Kexing Biological Products Co., Ltd Description and Business Overview
6.9.3 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.9.4 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.9.5 Beijing Kexing Biological Products Co., Ltd Recent Developments/Updates
6.10 Jiangsu Kangrun Biotechnology Co., Ltd
6.10.1 Jiangsu Kangrun Biotechnology Co., Ltd Corporation Information
6.10.2 Jiangsu Kangrun Biotechnology Co., Ltd Description and Business Overview
6.10.3 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.10.4 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.10.5 Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments/Updates
6.11 Hualan Bio Vaccines Co., Ltd
6.11.1 Hualan Bio Vaccines Co., Ltd Corporation Information
6.11.2 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview
6.11.3 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.11.4 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.11.5 Hualan Bio Vaccines Co., Ltd Recent Developments/Updates
6.12 Dalian Yalifeng Biopharmaceutical Co., Ltd
6.12.1 Dalian Yalifeng Biopharmaceutical Co., Ltd Corporation Information
6.12.2 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview
6.12.3 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.12.4 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.12.5 Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments/Updates
6.13 Shanghai Institute of Biological Products Co., Ltd
6.13.1 Shanghai Institute of Biological Products Co., Ltd Corporation Information
6.13.2 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview
6.13.3 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.13.4 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.13.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments/Updates
6.14 Changchun Institute of Biological Products Co., Ltd
6.14.1 Changchun Institute of Biological Products Co., Ltd Corporation Information
6.14.2 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview
6.14.3 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.14.4 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.14.5 Changchun Institute of Biological Products Co., Ltd Recent Developments/Updates
6.15 Lanzhou Institute of Biological Products Co., Ltd
6.15.1 Lanzhou Institute of Biological Products Co., Ltd Corporation Information
6.15.2 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview
6.15.3 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.15.4 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.15.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
6.16 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
6.16.1 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Corporation Information
6.16.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview
6.16.3 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.16.4 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.16.5 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments/Updates
6.17 Emmi Chengxin Biopharmaceutical Co., Ltd
6.17.1 Emmi Chengxin Biopharmaceutical Co., Ltd Corporation Information
6.17.2 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Description and Business Overview
6.17.3 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.17.4 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
6.17.5 Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Inactivated Influenza Virus Vaccine Industry Chain Analysis
7.2 Inactivated Influenza Virus Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Inactivated Influenza Virus Vaccine Production Mode & Process
7.4 Inactivated Influenza Virus Vaccine Sales and Marketing
7.4.1 Inactivated Influenza Virus Vaccine Sales Channels
7.4.2 Inactivated Influenza Virus Vaccine Distributors
7.5 Inactivated Influenza Virus Vaccine Customers
8 Inactivated Influenza Virus Vaccine Market Dynamics
8.1 Inactivated Influenza Virus Vaccine Industry Trends
8.2 Inactivated Influenza Virus Vaccine Market Drivers
8.3 Inactivated Influenza Virus Vaccine Market Challenges
8.4 Inactivated Influenza Virus Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Inactivated Influenza Virus Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Inactivated Influenza Virus Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Inactivated Influenza Virus Vaccine Market Competitive Situation by Manufacturers in 2022
Table 4. Global Inactivated Influenza Virus Vaccine Sales (K Units) of Key Manufacturers (2024-2024)
Table 5. Global Inactivated Influenza Virus Vaccine Sales Market Share by Manufacturers (2024-2024)
Table 6. Global Inactivated Influenza Virus Vaccine Revenue (US$ Million) by Manufacturers (2024-2024)
Table 7. Global Inactivated Influenza Virus Vaccine Revenue Share by Manufacturers (2024-2024)
Table 8. Global Market Inactivated Influenza Virus Vaccine Average Price (US$/Unit) of Key Manufacturers (2024-2024)
Table 9. Global Key Players of Inactivated Influenza Virus Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Inactivated Influenza Virus Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Inactivated Influenza Virus Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Inactivated Influenza Virus Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Inactivated Influenza Virus Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Influenza Virus Vaccine as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Inactivated Influenza Virus Vaccine Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 17. Global Inactivated Influenza Virus Vaccine Sales by Region (2024-2024) & (K Units)
Table 18. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2024-2024)
Table 19. Global Inactivated Influenza Virus Vaccine Sales by Region (2024-2034) & (K Units)
Table 20. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2024-2034)
Table 21. Global Inactivated Influenza Virus Vaccine Revenue by Region (2024-2024) & (US$ Million)
Table 22. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2024-2024)
Table 23. Global Inactivated Influenza Virus Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2024-2034)
Table 25. North America Inactivated Influenza Virus Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 26. North America Inactivated Influenza Virus Vaccine Sales by Country (2024-2024) & (K Units)
Table 27. North America Inactivated Influenza Virus Vaccine Sales by Country (2024-2034) & (K Units)
Table 28. North America Inactivated Influenza Virus Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 29. North America Inactivated Influenza Virus Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Inactivated Influenza Virus Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Inactivated Influenza Virus Vaccine Sales by Country (2024-2024) & (K Units)
Table 32. Europe Inactivated Influenza Virus Vaccine Sales by Country (2024-2034) & (K Units)
Table 33. Europe Inactivated Influenza Virus Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 34. Europe Inactivated Influenza Virus Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Region: 2024 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Inactivated Influenza Virus Vaccine Sales by Region (2024-2024) & (K Units)
Table 37. Asia Pacific Inactivated Influenza Virus Vaccine Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Region (2024-2024) & (US$ Million)
Table 39. Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Inactivated Influenza Virus Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Inactivated Influenza Virus Vaccine Sales by Country (2024-2024) & (K Units)
Table 42. Latin America Inactivated Influenza Virus Vaccine Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Inactivated Influenza Virus Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 44. Latin America Inactivated Influenza Virus Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Inactivated Influenza Virus Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Inactivated Influenza Virus Vaccine Sales by Country (2024-2024) & (K Units)
Table 47. Middle East & Africa Inactivated Influenza Virus Vaccine Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Inactivated Influenza Virus Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 49. Middle East & Africa Inactivated Influenza Virus Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Inactivated Influenza Virus Vaccine Sales (K Units) by Type (2024-2024)
Table 51. Global Inactivated Influenza Virus Vaccine Sales (K Units) by Type (2024-2034)
Table 52. Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2024-2024)
Table 53. Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2024-2034)
Table 54. Global Inactivated Influenza Virus Vaccine Revenue (US$ Million) by Type (2024-2024)
Table 55. Global Inactivated Influenza Virus Vaccine Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2024-2024)
Table 57. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2024-2034)
Table 58. Global Inactivated Influenza Virus Vaccine Price (US$/Unit) by Type (2024-2024)
Table 59. Global Inactivated Influenza Virus Vaccine Price (US$/Unit) by Type (2024-2034)
Table 60. Global Inactivated Influenza Virus Vaccine Sales (K Units) by Application (2024-2024)
Table 61. Global Inactivated Influenza Virus Vaccine Sales (K Units) by Application (2024-2034)
Table 62. Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2024-2024)
Table 63. Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2024-2034)
Table 64. Global Inactivated Influenza Virus Vaccine Revenue (US$ Million) by Application (2024-2024)
Table 65. Global Inactivated Influenza Virus Vaccine Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2024-2024)
Table 67. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2024-2034)
Table 68. Global Inactivated Influenza Virus Vaccine Price (US$/Unit) by Application (2024-2024)
Table 69. Global Inactivated Influenza Virus Vaccine Price (US$/Unit) by Application (2024-2034)
Table 70. CSL Corporation Information
Table 71. CSL Description and Business Overview
Table 72. CSL Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 73. CSL Inactivated Influenza Virus Vaccine Product
Table 74. CSL Recent Developments/Updates
Table 75. GSK Corporation Information
Table 76. GSK Description and Business Overview
Table 77. GSK Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 78. GSK Inactivated Influenza Virus Vaccine Product
Table 79. GSK Recent Developments/Updates
Table 80. Sanofi Pasteur Corporation Information
Table 81. Sanofi Pasteur Description and Business Overview
Table 82. Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 83. Sanofi Pasteur Inactivated Influenza Virus Vaccine Product
Table 84. Sanofi Pasteur Recent Developments/Updates
Table 85. Mylan Corporation Information
Table 86. Mylan Description and Business Overview
Table 87. Mylan Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 88. Mylan Inactivated Influenza Virus Vaccine Product
Table 89. Mylan Recent Developments/Updates
Table 90. AstraZeneca Corporation Information
Table 91. AstraZeneca Description and Business Overview
Table 92. AstraZeneca Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 93. AstraZeneca Inactivated Influenza Virus Vaccine Product
Table 94. AstraZeneca Recent Developments/Updates
Table 95. Pfizer Corporation Information
Table 96. Pfizer Description and Business Overview
Table 97. Pfizer Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 98. Pfizer Inactivated Influenza Virus Vaccine Product
Table 99. Pfizer Recent Developments/Updates
Table 100. Johnson & Johnson Corporation Information
Table 101. Johnson & Johnson Description and Business Overview
Table 102. Johnson & Johnson Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 103. Johnson & Johnson Inactivated Influenza Virus Vaccine Product
Table 104. Johnson & Johnson Recent Developments/Updates
Table 105. Jiangsu Jindik Biotechnology Co., Ltd Corporation Information
Table 106. Jiangsu Jindik Biotechnology Co., Ltd Description and Business Overview
Table 107. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 108. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 109. Jiangsu Jindik Biotechnology Co., Ltd Recent Developments/Updates
Table 110. Beijing Kexing Biological Products Co., Ltd Corporation Information
Table 111. Beijing Kexing Biological Products Co., Ltd Description and Business Overview
Table 112. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 113. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 114. Beijing Kexing Biological Products Co., Ltd Recent Developments/Updates
Table 115. Jiangsu Kangrun Biotechnology Co., Ltd Corporation Information
Table 116. Jiangsu Kangrun Biotechnology Co., Ltd Description and Business Overview
Table 117. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 118. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 119. Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments/Updates
Table 120. Hualan Bio Vaccines Co., Ltd Corporation Information
Table 121. Hualan Bio Vaccines Co., Ltd Description and Business Overview
Table 122. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 123. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 124. Hualan Bio Vaccines Co., Ltd Recent Developments/Updates
Table 125. Dalian Yalifeng Biopharmaceutical Co., Ltd Corporation Information
Table 126. Dalian Yalifeng Biopharmaceutical Co., Ltd Description and Business Overview
Table 127. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 128. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 129. Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments/Updates
Table 130. Shanghai Institute of Biological Products Co., Ltd Corporation Information
Table 131. Shanghai Institute of Biological Products Co., Ltd Description and Business Overview
Table 132. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 133. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 134. Shanghai Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 135. Changchun Institute of Biological Products Co., Ltd Corporation Information
Table 136. Changchun Institute of Biological Products Co., Ltd Description and Business Overview
Table 137. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 138. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 139. Changchun Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 140. Lanzhou Institute of Biological Products Co., Ltd Corporation Information
Table 141. Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
Table 142. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 143. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 144. Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 145. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Corporation Information
Table 146. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Description and Business Overview
Table 147. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 148. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 149. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments/Updates
Table 150. Emmi Chengxin Biopharmaceutical Co., Ltd Corporation Information
Table 151. Emmi Chengxin Biopharmaceutical Co., Ltd Description and Business Overview
Table 152. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 153. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product
Table 154. Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments/Updates
Table 155. Key Raw Materials Lists
Table 156. Raw Materials Key Suppliers Lists
Table 157. Inactivated Influenza Virus Vaccine Distributors List
Table 158. Inactivated Influenza Virus Vaccine Customers List
Table 159. Inactivated Influenza Virus Vaccine Market Trends
Table 160. Inactivated Influenza Virus Vaccine Market Drivers
Table 161. Inactivated Influenza Virus Vaccine Market Challenges
Table 162. Inactivated Influenza Virus Vaccine Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Inactivated Influenza Virus Vaccine
Figure 2. Global Inactivated Influenza Virus Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Inactivated Influenza Virus Vaccine Market Share by Type in 2022 & 2034
Figure 4. Whole Virus Vaccine Product Picture
Figure 5. Subunit Vaccine Product Picture
Figure 6. Global Inactivated Influenza Virus Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Inactivated Influenza Virus Vaccine Market Share by Application in 2022 & 2034
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Global Inactivated Influenza Virus Vaccine Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 11. Global Inactivated Influenza Virus Vaccine Market Size (2024-2034) & (US$ Million)
Figure 12. Global Inactivated Influenza Virus Vaccine Sales (2024-2034) & (K Units)
Figure 13. Global Inactivated Influenza Virus Vaccine Average Price (US$/Unit) & (2024-2034)
Figure 14. Inactivated Influenza Virus Vaccine Report Years Considered
Figure 15. Inactivated Influenza Virus Vaccine Sales Share by Manufacturers in 2022
Figure 16. Global Inactivated Influenza Virus Vaccine Revenue Share by Manufacturers in 2022
Figure 17. The Global 5 and 10 Largest Inactivated Influenza Virus Vaccine Players: Market Share by Revenue in 2022
Figure 18. Inactivated Influenza Virus Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 19. Global Inactivated Influenza Virus Vaccine Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Figure 20. North America Inactivated Influenza Virus Vaccine Sales Market Share by Country (2024-2034)
Figure 21. North America Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2024-2034)
Figure 22. United States Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 23. Canada Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 24. Europe Inactivated Influenza Virus Vaccine Sales Market Share by Country (2024-2034)
Figure 25. Europe Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2024-2034)
Figure 26. Germany Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 27. France Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 28. U.K. Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 29. Italy Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 30. Russia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 31. Asia Pacific Inactivated Influenza Virus Vaccine Sales Market Share by Region (2024-2034)
Figure 32. Asia Pacific Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2024-2034)
Figure 33. China Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 34. Japan Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 35. South Korea Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 36. India Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 37. Australia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 38. China Taiwan Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 39. Southeast Asia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 40. Latin America Inactivated Influenza Virus Vaccine Sales Market Share by Country (2024-2034)
Figure 41. Latin America Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2024-2034)
Figure 42. Mexico Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 43. Brazil Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 44. Argentina Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 45. Middle East & Africa Inactivated Influenza Virus Vaccine Sales Market Share by Country (2024-2034)
Figure 46. Middle East & Africa Inactivated Influenza Virus Vaccine Revenue Market Share by Country (2024-2034)
Figure 47. Turkey Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 48. Saudi Arabia Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 49. UAE Inactivated Influenza Virus Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 50. Global Sales Market Share of Inactivated Influenza Virus Vaccine by Type (2024-2034)
Figure 51. Global Revenue Market Share of Inactivated Influenza Virus Vaccine by Type (2024-2034)
Figure 52. Global Inactivated Influenza Virus Vaccine Price (US$/Unit) by Type (2024-2034)
Figure 53. Global Sales Market Share of Inactivated Influenza Virus Vaccine by Application (2024-2034)
Figure 54. Global Revenue Market Share of Inactivated Influenza Virus Vaccine by Application (2024-2034)
Figure 55. Global Inactivated Influenza Virus Vaccine Price (US$/Unit) by Application (2024-2034)
Figure 56. Inactivated Influenza Virus Vaccine Value Chain
Figure 57. Inactivated Influenza Virus Vaccine Production Process
Figure 58. Channels of Distribution (Direct Vs Distribution)
Figure 59. Distributors Profiles
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed